Trials / Completed
CompletedNCT00496509
Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer
A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 (Zactima) 100mg | |
| PROCEDURE | Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) | |
| PROCEDURE | Biomarker Draws | |
| DRUG | ZD6474 (Zactima) 300mg |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2007-07-04
- Last updated
- 2016-08-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00496509. Inclusion in this directory is not an endorsement.